rhenium (186Re) obisbemeda

The drug 186RNL, also known as rhenium (186Re) obisbemeda or Rhenium-186-NanoLiposome, is a novel radiopharmaceutical developed for targeted cancer therapy. It consists of radioactive rhenium-186 chelated with BMEDA (bis(2-mercaptoethyl)diamine) and encapsulated in nanoliposomes. This formulation enables targeted delivery of radiation directly to tumor sites while minimizing exposure to healthy tissues. Rhenium-186 emits beta radiation with approximately 2mm tissue path length for precise tumor targeting and gamma energy that enables real-time imaging of treatment distribution. It has a half-life of approximately 90 hours that provides optimal therapeutic radiation delivery. The nanoliposomal encapsulation helps retain the radioisotope at the tumor site, allowing for high radiation doses to be delivered locally while minimizing systemic exposure. It is administered through different routes depending on the cancer type: For glioblastoma, convection enhanced delivery (CED) directly into the tumor, bypassing the blood-brain barrier; for leptomeningeal metastases, intraventricular administration via an Ommaya reservoir directly into the cerebrospinal fluid. Clinical trials (ReSPECT-GBM for recurrent glioblastoma and ReSPECT-LM for leptomeningeal metastases) are ongoing, showing promising safety and efficacy profiles. In recurrent glioblastoma, doses exceeding 100 Gy showed significant survival advantage (22.9 months vs 5.6 months), with the average absorbed dose to tumors being 309.14 Gy. Treatment was generally safe with mostly mild to moderate adverse events. In leptomeningeal metastases, preliminary results show good tolerability with no dose-limiting toxicities, decreases in CSF tumor cell counts ranging from 50-92%, and absorbed doses ≥20 Gy to ventricles and cranial subarachnoid spaces. Additional studies for pediatric brain cancers are planned or in progress.

Brand names

REYOBIQ

Other names

Rhenium-186-NanoLiposomeRhenium186-NanoLiposomeRhenium 186-NanoLiposome